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Abstract
Background: We undertook a study to evaluate the clinical relevance of miR-92a in plasma obtained from non-Hodgkin’s
lymphoma (NHL) patients, because the miR-17-92 polycistronic miRNA cluster plays a crucial role in lymphomagenesis and
affects neo-angiogenesis.
Methodology/Principal Findings: Plasma miR-92a values in NHL were extremely low (,5%), compared with healthy
subjects (P,.0001), irrespective of lymphoma sub-type. The very low plasma level of miR-92a increased in the complete
response (CR) phase but did not reach the normal range, and the plasma level was lower again in the relapse phase. Patients
in CR or CR unconfirmed with a plasma miR-92a level of less than the cut-off level showed a significantly high relapse rate
compared with patients with normalized plasma miR-92a level.
Conclusions/Significance: The current results therefore indicate that the plasma miR-92a value could be a novel biomarker
not only for diagnosis but also for monitoring lymphoma patients after chemotherapy.
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Introduction
MicroRNAs (miRNAs) are small non-coding RNAs that range
from 18 to 24 nucleotides in length and regulate gene expression
by the RNA-induced silencing complex, resulting in a reduction of
the translation and stability of target messenger RNAs [1–3].
Recent studies have shown the presence of miRNA alterations in
various human cancers, suggesting that miRNAs play important
roles in carcinogenesis and disease progression [4–6]. The miR-
17-92 cluster is a polycistronic miRNA gene, encoding six
miRNAs (miR-17, miR-18a, miR-19a, miR-19b, miR-20a, and
miR-92). Several lines of evidence have suggested the importance
of the miR-17-92 cluster in immune cell development, as well as in
tumorigenesis in lymphoid tissue [7–9]. In mouse experiments,
MYC regulates the miR-17-92 cluster [7,9,10] whose ectopic
expression in lymphocytes is associated with severe lymphoprolif-
erative disorders owing to the targeting of BIM, a proapoptotic
member of the anti-apoptotic BCL2 family [9]. In humans, over-
expression of the miR-17-92 cluster has been demonstrated in
various neoplasms, including lymphoma, multiple myeloma,
ovarian cancer, and lung cancer [11–15], perhaps owing to
possible induction of anti-apoptosis.
Activation of the miR-17-92 pathway triggered by MYC may in
part affect augmentation of tumor angiogenesis: Dews et al.
demonstrated that MYC-transformed colonocyte-bearing mice
showed an enhancement of tumor neo-angiogenesis with down-
regulated thrombospodin-1 and connective growth factor [16]. In
contrast, members of the miR-17-92 cluster have recently been
identified to have cell intrinsic anti-angiogenic function in human
endothelial cells [17]. MiR-92a is known to control angiogenesis in an
ischemic mice model [18], and involvement of angiogenesis is crucial
in the progression of lymphoma or multiple myeloma patients [19,20].
Recently, studies have demonstrated that circulating miRNAs
can be detected in the plasma and serum of healthy subjects and
cancer patients [21–24], including those with lymphoma [25].
Therefore, deviations in levels of certain miRNAs detected in the
plasmaof cancer patients could be a usefuland non-invasive marker
to detect cancer development. We have recently demonstrated that
miR-92a dramatically decreased in the plasma of acute leukemia
patients [26]. This evidence allows us to examine the miR-92a
expression levels in plasma obtained from patients with lymphoma
and clarify the clinical relevance of plasma levels of miR-92a, given
that the miR-17-92 cluster is crucial in lymphomagenesis.
Results
Microarray analysis of miRNAs in the plasma of
lymphoma
To identify the differentially expressed miRNAs in the plasmas of
NHL patients, we first screened NHL samples using microarrays.
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plasma of diffuse large B-cell lymphoma (DLBCL) samples (n=4),
follicular lymphoma (FL) samples (n=4), and healthy controls
(n=8). Total RNA in each group was pooled and used for
microarray experiments. The signals of miR-638 from normal
subjects constituted the top rank, regardless of sex or age [26]. Our
data showed that the miR-638 probe had the highest intensity in all
DLBCL (Figure 1A) and FL (Figure 1B) samples; therefore, we
applied miR-638 signal values for normalization. By contrast, we
found that signal intensities of miR-92 were dramatically reduced in
both FL and DLBCL samples compared with healthy controls
(Figure 1C).
Validation of plasma miR-92a expression level
The results obtained from the microarray analysis described the
stable detection and reproducible results of the miR-638 expression
level in plasma. Since we could not detect plasma U6B, which is
commonly used as an internal standard for miRNA expression
analysis in cells, we used miR-638 as a reference in each sample, as
previously reported [26,27]. From these results, we obtained
expression levels of miR-92a (i.e., miR-92a/miR-638), and took
the result to be the miR-92a plasma level. Moreover, we confirmed
that plasma miR-92a expression could represent miR-17-92a
polycistronic miRNA in lymphoma patients (Figure 2A). We were
unable to detect plasma miR-638 expression in two lymphoma
patients by the quantitative real-time PCR method; therefore, we
regarded these two specimens as PCR failures and excluded their
resultsfromthe statisticalanalysis.WedeterminedmiR-92alevelsin
37 plasma specimensfrom healthysubjectsandperformedstatistical
analysis using 144 specimens from NHL patients.
Decreased plasma miR-92a levels at diagnosis of
lymphoma
We found significantly lower plasma level values of miR-92a at
diagnosis, compared with those of normal subjects, regardless of
lymphoma sub-type (P,.0001; Figure 2B). The expression level of
plasma miR-92a in patients with NHL was less than 5% that of healthy
volunteers. Among lymphoma sub-types, the plasma miR-92a level did
not differ between DLBCL and FL (P=.927) at diagnosis; however,
the plasma miR-92a level in T-cell lymphoma tended to be higher than
that in FL (P=.014) or DLBCL (P=.057) (Table S1).
We determined the sensitivity and specificity using receiver
operating characteristic (ROC) curve analysis. The area under the
ROC curve was 0.9954. When the cut-off level of plasma miR-
92a/miR-638 in all 60 NHL patients at diagnosis was 0.2165, the
sensitivity was 91.85% (95% confidence interval [CI]: 81.32% to
97.19%), and the specificity was 97.3% (95% CI: 85.84% to
99.93%) (Figure 2C). We then analyzed the 0.2165 cut-off value
of miR-92a/miR-638 to determine clinical significance.
Clinical relevance of plasma miR-92a at various states
The plasma miR-92a level at diagnosis did not differ according
to clinical stage among DLBCL patients (Figure 3A). Plasma
miR-92a levels in DLBCL patients in CR increased significantly
compared with the level at diagnosis (P,.0001) but were still
significantly lower than those in healthy individuals (P,.0001). In
the relapse phase, plasma miR-92a levels again decreased
(P,.0001), and these levels were similar to those at the time of
diagnosis (P=.8132; Figure 3A). Similarly, a significantly low
level of plasma miR-92a was noted in patients with FL at the time
of diagnosis (P,.0001), but it partially normalized after the
patients obtained CR and decreased again in the relapse phase.
The plasma miR-92a level in FL patients classified as CRu was
decreased compared with that of CR patients (P=.0186;
Figure 3B). At relapse, the plasma miR-92a level in FL patients
was significantly decreased compared with that of CR plus CRu
patients (P=.0089). The fluctuation pattern of plasma miR-92a
detection levels in relation to clinical status in T-cell NHL was
similar to that of DLBCL and FL (Figure 3C).
Relapse risk analysis
Of the patients with CR (including CRu in FL) at the time of
examination of plasma miR-92a who had been followed up for
Figure 1. Comparison of miR expressions in the plasma of
normal subjects and non-Hodgkin’s lymphoma patients by
MiRNA microarray. Comparison of normalized signal intensities of
various miRs in plasmas (miR-638 adjusted to 1000). X axis represents
healthy control (Ctrl), and Y axis represents diffuse large B-cell
lymphoma (DLBCL) (A) or follicular lymphoma (FL) (B). Red squares
show miR-638 (control) and miR-92a. (C) Comparison of the ratio of
miR92/miR-638 signal intensity in the plasma of Ctrl, FL, and DLBCL.
doi:10.1371/journal.pone.0016408.g001
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stem cell transplantation, a significant higher relapse rate was
evident in patients showing low plasma miR-92a levels (below the
0.2165 cut-off level) compared with those with normalized plasma
miR-92a (above 0.2165). DLBCL patients with low plasma miR-
92a relapsed significantly compared with those with normal range
plasma miR-92a (5/12 versus 1/22; P=.007 by the chi-square
Figure 2. Plasma miR-92a expression level and ROC curve in
patients with non-Hodgkin’s lymphoma by quantitative real-
time PCR. (A) Plasma miR-17-92a expression levels in normal subjects
(open bars: Normal: n=5) and diffuse large B-cell lymphoma (solid bars:
DLBCL: n=13), indicating that all of these miR-17-92a polycistronic miRs
were remarkably decreased in plasma obtained from DLBCL patients.
Boxes show 95 percentile confidence intervals and lines indicate the
range of each miR values. (B) Plasma miR-92a value (miR-92a/miR-638)
in healthy subjects, and in patients with diffuse large B-cell lymphoma,
follicular lymphoma, and T-cell non-Hodgkin’s lymphoma (T-NHL) at
diagnosis. Boxes show 95 percentile confidence intervals; lines indicate
the range of miR-92a values and also show significantly low levels of
plasma miR-92a in various lymphomas, compared with healthy subjects
(P,.0001). (C) ROC curve analysis using GraphPad Prism 5.0 software.
The cut-off level of plasma miR-92a/miR-638 in all non-Hodgkin’s
lymphoma patients (n=60) was 0.2165; the sensitivity was 91.85% (95%
CI: 81.32% to 97.19%) and specificity was 97.3% (95% CI: 85.84% to
99.93%).
doi:10.1371/journal.pone.0016408.g002
Figure 3. Plasma miR-92a value (miR-92a/miR-638) in patients
with non-Hodgkin’s lymphoma at various stages. (A) Plasma
miR-92a value (miR-92a/miR-638) in patients with diffuse large B-cell
lymphoma at the time of diagnosis, in the relapse phase, and in the
complete remission (CR) state. Decreased plasma miR-92a values
recovered in the CR phase (P,.0001) but were still significantly lower
than in normal subjects (P,.0001). Plasma miR-92a levels at relapse
decreased again and the levels were similar to those at diagnosis. (B)
Plasma miR-92a value (miR-92a/638) in patients with follicular
lymphoma at the time of diagnosis (Dx), in the relapse phase, and in
the CR or complete remission unconfirmed (CRu) states. Patients with
CRu status had significantly lower plasma miR-92a/miR-638 values
compared with those who had CR (P=.0186 by the Mann-Whitney test).
(C) Plasma miR-92a values (miR-92a/miR-638) in patients with T-cell
non-Hodgkin’s lymphoma at the time of diagnosis, relapse phase, and
complete remission (CR and CRu).
doi:10.1371/journal.pone.0016408.g003
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92a value was 15 (95% CI: 1.486 to 151.4) by univariate analysis.
Although the number of study patients with DLBCL was small,
the link between low plasma miR-92a values in CR and the
relapse rate was notable, but not significant, in patients with
advanced clinical stage (III and IV) at diagnosis (3/5 versus 2/13;
P=.0584) and in those with higher International Prognostic
Scores (IPI) (2/4 versus 1/10; P=.0994). Multivariate analysis
revealed that only down-regulated plasma miR-92a was signifi-
cantly lower in relapsed DLBCL patients (P=.02). In addition, the
corrected odds ratio was 16.232 (95% CI: 1.562 to 168.725),
compared with that of the normalized plasma miR-92a value
determined at the clinical CR phase (Table 1).
In FL patients, the relapse rate was high in patients with low
plasma miR-92a in CR + CRu (5/8 versus 1/11; P=.013). The
odds ratio for relapse in the low plasma miR-92a group was 16.67
(95% CI: 1.361 to 204.2), but other markers were not statistically
significant (Table 2). These data suggest the possibility that plasma
miR-92a levels could be a biomarker to predict relapse, even in
patients with clinically determined CR or CRu in FL. Multivariate
analysis demonstrated that a low plasma miR-92a level did not
reach statistical significance in predicting relapse owing to the
insufficient number of examined patients (data not shown).
MiR-92a expression in lymphoma tissue
We also examined the expression levels of miR-92a in
lymphoma tissues. We performed in situ hybridization using
LNA-modified probes labeled with digoxigenin. We examined 2
cases each of DLBCL and FL, and found that miR-92a was
strongly expressed in lymphoma cells from both DLBCL and FL.
However, miR-92a expression was not detected in lymph nodes
obtained from non-lymphoma patients (controls) (Figure 4).
Discussion
Detection of miRNAs in human plasma has recently been
demonstrated in healthy subjects, as well as in cancer-bearing
patients [21–27]. Mitchell et al. clearly demonstrated that
miRNAs are present in a stable form in human plasma and
serum, and miR-141 originating from human prostate cancer
showed the greatest differential expression in prostate cancer
serum specimens [21]. Therefore, elevation of certain circulating
miRNAs could indicate the presence of certain cancers. Recently,
Lawrie et al. also reported that various miRNAs, including miR-
155, miR-210, and miR-21, were elevated in the serum of DLBCL
patients, and that miR-21 expression was associated with relapse-
free survival [25].
Amplification and over-expression of cellular miR-17-92 has
been observed in hematologic malignancy, including B-cell
lymphoma [28–30], T-cell acute lymphoblastic leukemia [31],
and purified chronic myeloid leukemia cells [32]. In the current
study, however, we found extremely low plasma levels of miR-92a
in lymphoma patients compared with healthy individuals. The
reduced plasma miR-92a levels partially recovered after CR was
Table 1. Statistical analysis of relapse in diffuse large B cell lymphoma patients whose miR-92a levels were determined at
complete response phase.
univariate multivariate
Factors at diagnosis
No.
(n=34*)
Relpased
(n=6) P value odds ratio 95% CI P value
Corrected
odds ratio 95% CI
Sex
male 13 1 .231 0.267 0.02743 to 2.592 .833 1.3037 0.066 to 8.971
female 21 5
Age
$60 years 20 4 1 1.5 0.2346 to 9.593 .50 0.418 0.03 to 5.287
,60 years 14 2
LDH
Elevated 16 4 .289 2.667 0.4170 to 17.05 .673 1.625 0.170 to 15.522
Normal 18 2
B symptoms
Yes 16 3 .874 1.154 0.1976 to 6.738 .853 0.730 0.026 to 20.544
No 18 3
Clinical stage
III+IV 18 5 .18 5.769 0.5946 to 55.98 .062 23.189 0.858 to 629.583
I+II 16 1
International Prognostic Index
high + high-int 14 3 .628 1.545 0.2629 to 9.085 .972 0.943 0.038 to 23.744
low + low int 20 3
Plasma miR-92a
Low (,0.2165) 12 5 .007 15 1.486 to 151.4 .020 16.232 1.562 to 168.725
Normal ($0.2165) 22 1
Abbreviations: CI, confidence interval; LDH, lactate dehydrogenase.
*Patients who had been followed for more than 6 months and who did not receive any hematopoietic stem cell transplantation were analyzed.
doi:10.1371/journal.pone.0016408.t001
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that plasma miR-92a levels correlate with disease conditions in
lymphoma patients. The changes in plasma miR-92a levels in
various clinical states were also inversely correlated with b2-
microglobulin or lactate dehydrogenase levels (data not shown). In
the present series of lymphoma tissues, however, over-expression
of miR-92a was clearly shown using in situ hybridization.
Therefore, discrepancy of miR-92a levels between lymphoma
tissues and plasma might be of great import. In addition, we found
that miR-92a plasma levels in lymphoma patients were less than
5% that of healthy subjects, although the exact mechanism of
down-regulation of miR-92a in cancer-bearing patients is still
obscure. Shigoka et al also demonstrated the discrepancy of miR-
92a levels between tumor tissues and plasma in patients with
hepatocellular carcinoma [27].
Recently, it has been demonstrated that tumor-bearing hosts
down-regulate miR-17-92 in CD4
+ T cells, and it has been
postulated that a type-2-skewing tumor microenvironment induces
the down-regulation of miR-17-92 expression in T cells; CD4+ T
cells from patients with glioblastoma multiforme had extremely
low levels of 17-92 polycistronic miRNAs [33], suggesting the
possibility that the low plasma miR-17-92 level in lymphoma
Table 2. Statistical analysis of relapse in follicular lymphoma patients whose miR-92a levels were determined at complete
response and complete response uncertain phase.
univariate
Factors at diagnosis No. (n=19) Relpased (n=6) P value odds ratio 95% CI
Sex
male 10 3 .876 0.857 0.1235 to 5.947
female 9 3
Age
$60 years 9 4 .252 3.2 0.4192 to 24.43
,60 years 10 2
LDH
Elevated 2 0 .31 0.354 0.01463 to 8.559
Normal 17 6
Hemoglobin
#120 g/L 3 2 .154 6 0.4220 to 85.30
$120 g/L 16 4
Ann Arbor stage
III+IV 13 5 .342 3.125 0.2776 to 35.18
I+II 6 1
No. of nodal area involved
.4 6 2 .911 1.125 0.1425 to 8.884
#41 3 4
Bone marrow invasion
Yes 8 3 .636 1.6 0.2271 to 11.27
No 11 3
b2-microglobulin elevation*
Yes 8 3 .41 2.4 0.2910 to 19.79
No 10 2
FLIPI
High 3 1
Intermediate 8 3 .863
Low 8 2
FLIPI-2*
High 4 3
Intermediate 11 2 .047
Low 3 0
Plasma miR-92a
Low (,0.2165) 8 5 .013 16.67 1.361 to 204.2
Normal ($0.2165) 11 1
Abbreviations: CI, confidence interval; LDH, lactate dehydrogenase; FLIPI, Follicular Lymphoma International Prognostic Index.
*Data from 1 patient were missing.
doi:10.1371/journal.pone.0016408.t002
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miRs could be taken up and could function in the recipient cells,
including intercellular immune communication [34,35]. Because
some of our NHL patients who obtained CR did not show
normalization of plasma miR-92a levels and exhibited a
significantly high relapse rate, it is likely that low plasma miR-
92a levels may correlate with failure of anti-tumor immune
responses. In contrast, over-expression of miR-92a in lymphoma
cells may enhance neo-angiogenesis indirectly [16], while
angiogenesis progresses under conditions of reduced miR-92a
levels in endothelial cells [18]. Therefore, down-regulation of
plasma miR-92a levels is also possible and may be due to exosomal
transport to vascular endothelial cells. Most recently, Fichtlscherer
et al found that circulating levels of vascular (miR-126, miR-17
and miR-92a) and inflammation-associated miRNA (miR-155)
were significantly reduced in patients with coronary artery disease
[36]. Nevertheless, plasma miR-92a level seems to be unrelated to
lymphoma burden, because there was no significant difference
among clinical stages and miR-92a values in NHL patients.
Another possibility of down-regulation of plasma miR-17-92 in
lymphoma patients might be due to excess degradation of miR-17-
92 in plasma or epigenetic silencing [37,38], however, we have no
evidence for these possibilities in cancer-bearing patients.
The extremely low plasma miR-17-92 level might be a
representative reaction of lymphoma-bearing patients and is
associated with the hematologic condition. The clinically impor-
tant message is that low levels of plasma miR-92a in CR status are
linked to relapse. In the current study, low levels of plasma miR-
92a in the CR phase with NHL were related to a significantly high
relapse rate, suggesting that plasma miR-92a levels could be used
to monitor disease condition. This evidence is particularly clear in
FL and high-grade DLBCL patients. Although the number of
patients in this series is still small, the results may be useful in
determining a strategy for second-line therapy for NHL patients.
Therefore, a combination of classic anatomical assessment and
miR-92a levels could be a powerful tool for monitoring disease
status. Additional information regarding plasma miR-17-92
expression may emerge from studies of the pathophysiology of
the immune response of cancer-bearing patients and may also
provide a promising approach for immunotherapy or anti-neo-
angiogenesis therapy for cancer patients.
Materials and Methods
Patients and samples
We evaluated peripheral blood obtained from 126 patients (144
specimens) with non-Hodgkin’s lymphoma (NHL) after obtaining
their written informed consent: 76 patients (87 specimens) had
diffuse large B-cell lymphoma (DLBCL), 32 patients (36
specimens) had follicular lymphoma (FL), and 18 patients (21
specimens) had T-cell NHL. Of the 87 samples from patients with
DLBCL, 32 samples were studied at the time of diagnosis, 9 at
relapse, and 46 at the complete remission (CR) phase. Of the 46
samples, 11 patients were analyzed at both diagnosis and the CR
phase. The 36 specimens from patients with FL consisted of 12
samples at diagnosis, 11 at CR, 8 at CR unconfirmed (CRu), and 5
at relapse; 4 patients were studied at both diagnosis and CR/CRu.
Of the 21 samples from patients with T-cell NHL, 16 samples
were studied at the time of diagnosis, 2 at relapse, and 3 at the
CR/CRu phase; 3 patients were analyzed at both diagnosis and
the CR phase (Table S1). Patients were treated with standard
chemotherapy, for example, rituximab plus CHOP or CHOP-like
regimens for CD20-positive NHL and CHOP-based therapy for
T-cell NHL. Complete remission (CR) or CR unconfirmed (CRu)
Figure 4. In situ MiRNA expression in malignant lymphoma tissues. (A), (B) and (C) were diffuse large B-cell lymphoma. (D), (E) and (F) were
follicular lymphoma. (G), (H) and (I) were normal lymph node. (A), (D), (G), were H&E staining. (B), (C), (E), (F), (H) and (I) were in situ hybridization LNA
probes for miR-92a and in the negative control. Blue signals (BCIP/NBT) represent positive results for miR-92a. Nuclear staining (counter stains) was
nuclear fast red. We found positive signals for miR-92a in both nucleus and cytoplasm in (B) and (E). We could not detect positive signals in (G) and
scrambled control (C), (F) and (I). Bars indicate 50 mm.
doi:10.1371/journal.pone.0016408.g004
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statistical analysis, we utilized plasma from selected patients (53
out of 65 patients with CR + CRu) who had been followed-up for
more than 6 months after chemotherapy without any hematopoi-
etic stem cell transplantations. This study was approved by the
institutional review board of Tokyo Medical University (no. 930;
approved on June 24, 2008). Written informed consent was
obtained from all patients according to the Declaration of Helsinki
prior to collection of the specimens.
Total RNA in the plasma was isolated by using Isogen-LS
(Nippon Gene, Tokyo, Japan) according to the manufacturer’s
instructions. For RNA isolation from plasma, 250 ml of plasma was
homogenized in 750 ml of Isogen-LS, then 200 ml of chloroform
was added to the sample, and the mixed solution was centrifuged.
After additional chloroform extraction and precipitation with
isopropanol, the RNA sample was suspended in 20 ml of nuclease-
free water [26]. Usually, we obtained about 300 ng of RNA from
250 ml of plasma.
MiRNA microarray analysis
To monitor the changes in miRNA levels associated with NHL,
we labeled and hybridized 100 ng of total RNA using the Human
microRNA Microarray Kit (Agilent Technologies, Wilmington,
DE, USA) according to the manufacturer’s protocol (Protocol for
Use with Agilent MicroRNA Microarrays Version 1.5). Hybrid-
ization signals were detected with a G2505C microarray scanner
(Agilent Technologies), and the scanned images were analyzed
with Agilent feature extraction software 10.7.0. according to the
default protocol [26] All data is MIAME compliant, and the data
discussed in this manuscript have been deposited in NCBI’s Gene
Expression Omnibus and are accessible through GEO Series
accession number GSE22604: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?token=jxkzbkecqkqscdy&acc=GSE22604.
Quantitative real-time PCR of mature miRNAs
We quantified miRNAs using TaqManH MicroRNA Assays
(Applied Biosystems, Foster City, CA, USA) with modifications
[26] and miRNA-specific stem-loop primers (has-miR-92a,
000431; has-miR-638, 001582; Applied Biosystems). Subsequent-
ly, quantitative real-time polymerase chain reaction (PCR) was
performed with an ABI Prism 7000 sequence detection system
(Applied Biosystems). The reaction was initiated by incubation at
95uC for 2 min, followed by 50 cycles of 95uC for 15 sec and then
60uC for 1 min. All reactions were run in duplicate. Mean cycle
threshold (Ct) values for all miRNAs were quantified with
sequence detection system software (SDS Version 1.02; Applied
Biosystems). The miR-92a expression was normalized to miR-638
expression, yielding a –DCt value. The –DDCt value was then
calculated by subtracting the –DCt value of a normal sample from
the respective –DCt values of the patient samples. Expression of
miR-92a was normalized by using the 2
-DDCt method [26,27].
We also analyzed plasma miR-17-92a expression using
TaqManH MicroRNA Assays (Applied Biosystems) and miRNA-
specific stem-loop primers (has-miR-17, 002308; has-miR-18a,
002422; has-miR-19a, 000395; has-miR-19b, 000396; and has-
miR-20a, 000580 [Applied Biosystems]).
MiR-92a expression in the lymphoma cells
Locked nucleic acid (LNA)-modified probes for miR-92a and
negative control (miRCURY-LNA detection probe, Exiqon,
Vedbaek, Denmark) were used to detect miR-92a expression in
biopsied lymph nodes. The probe sequences were as follows: miR-
92a, 59-ACAGGCCGGGACAAGTGCAATA-39, scrambled oligonu-
cleotides used for the negative control, 59-GTGTAACACGTCTA-
TACGCCCA-39. In situ hybridization was performed with the
RiboMap in situ hybridization kit (Ventana Medical Systems,
Tucson, AZ, USA) on a Ventana Discovery automated in situ
hybridization instrument (Ventana Medical Systems) [26,27].
Statistical analysis
We used GraphPad Prism 5.0 software (GraphPad Software
Inc., San Diego, CA, USA) for statistical analysis. The Mann-
Whitney and chi-square tests were used to determine statistical
significances between the control and test groups. Multivariate
analysis was performed with Excel Multivariate Analysis Version
5.0 (Esumi KK, Tokyo, Japan). P values less than.05 were
considered to indicate statistically significant differences.
Supporting Information
Table S1 Plasma miR-92a/miR-638 expression levels in
non-Hodgkin’s lymphoma.
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